Aytu BioPharma Inc. (AYTU) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

Aytu BioPharma Inc.

NASDAQ: AYTU · Real-Time Price · USD
1.90
-0.07 (-3.55%)
At close: Oct 03, 2025, 3:59 PM
1.95
2.63%
After-hours: Oct 03, 2025, 07:58 PM EDT

Aytu BioPharma Income Statement

Financials in USD. Fiscal year is July - June.
Fiscal Year Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Revenue
66.38M 69.22M 64.8M 71.51M 72.75M 85.51M 94.22M 97.56M 107.4M 104.11M 105.58M 102.43M 96.67M 92.7M 81.99M 74.01M 65.63M 57.01M 51.68M 39.71M
Cost of Revenue
20.55M 21.74M 22.39M 21.1M 23.83M 29.93M 33.62M 38.46M 40.77M 41.2M 42.73M 44.57M 44.39M 43.96M 46.13M 41.3M 35.68M 28.07M 16.39M 11M
Gross Profit
45.83M 47.48M 46.37M 50.19M 51.24M 57.9M 58.95M 61.64M 66.63M 62.91M 62.85M 57.86M 52.28M 48.74M 35.85M 32.7M 29.95M 28.94M 35.3M 28.72M
Operating Income
-7.83M -3.85M -8.74M -3.9M -4.47M -653K -7.48M -14.82M -14.84M -12.3M 31.09M 23.99M -2.18M -28.96M -88.73M -83.01M -58.87M -41.43M -20.56M -19.95M
Interest Income
n/a n/a n/a n/a n/a 2K 4K 4K 4K 2K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-13.74M 1.78M -4.68M -4.46M -14.08M -12.61M -17.17M -24.47M -19.23M -34.48M -80.35M -85.21M -110.28M -111.32M -83.71M -81.68M -58.03M -42.44M -22.31M -13M
Net Income
-13.56M 1.64M -5.25M -6.25M -15.85M -13.69M -18M -24.47M -17.05M -30.68M -76.77M -81.63M -108.78M -111.69M -83.86M -81.84M -58.3M -42.45M -22.32M -13M
Selling & General & Admin
38.28M 40.9M 43.58M 43.88M 47.48M 50.48M 58.47M 67.03M 70.08M 73.38M 70.76M 69.79M 69.88M 73.22M 68.46M 62.13M 55.87M 48.77M 45.67M 40.9M
Research & Development
1.33M 2.15M 2.61M 2.61M 2.79M 2.21M 2.45M 3.63M 4.09M 7.33M 10.2M 13.41M 14.44M 15.51M 12.17M 7.54M 5.62M 2.36M 2.05M 1.83M
Other Expenses
9.17M 8.29M 8.91M 7.59M 4.81M 133K -216K 67K 2.34M 4.45M 4.31M 3.13M 1.89M 546K -940.42K -1.34M -2.05M -2.98M -3.09M -3.16M
Operating Expenses
48.78M 51.34M 55.11M 54.09M 55.08M 55.27M 63.15M 73.18M 78.96M 85.15M 85.26M 87.37M 88.39M 93.19M 90.16M 81.29M 73.84M 63.82M 55.66M 48.47M
Interest Expense
3.7M 7.76M 8.12M 8.31M 8.6M 3.81M 2.55M 3.78M 3.86M 24.21M 111.39M 109.42M 147.45M 141.75M 54.57M 54.04M 14.65M n/a n/a n/a
Selling & Marketing Expenses
20.91M 22.54M 23.89M 23.84M 24.27M 25.84M 32.09M 37.44M 41.45M 43.48M 40.42M 39.52M 38.71M 40.88M 37.73M 33.78M 30.31M 29.53M 22.93M 17.23M
Cost & Expenses
65.95M 73.08M 72.42M 70.11M 71.29M 77.59M 94.23M 109.1M 119.73M 126.36M 127.99M 131.94M 132.77M 137.15M 136.29M 122.59M 109.53M 91.89M 72.05M 59.47M
Income Tax Expense
681K 939K 1.34M 2.45M 2.04M 1.35M -530K -1.36M -2K 20.35M 108.89M 108.89M 107.42M 87.33M 12.02M 19.55M 20.4M 20.14M 8.27M -9.21M
Shares Outstanding (Basic)
6.79M 6.13M 6.13M 7.37M 5.54M 5.53M 5.52M 5.48M 4.06M 3.73M 3.11M 2.52M 1.8M 1.48M 1.32M 60K 1.18M 900K 660K 610K
Shares Outstanding (Diluted)
6.79M 8.2M 8.49M 9.1M 5.54M 5.53M 5.52M 5.48M 4.06M 3.73M 3.11M 2.52M 1.8M 1.48M 1.32M 60K 1.18M 900K 660K 610K
EPS (Basic)
-2.05 0.04 -1.13 -1.19 -2.87 -2.63 -4.04 -6.15 -4.95 -13.31 -47.28 -53.87 -488.79 -496.04 -488.34 -494 -65.8 -55.2 -57.2 -45.2
EPS (Diluted)
-2.81 -0.72 -1.45 -1.23 -2.87 -2.63 -4.04 -6.15 -4.95 -13.31 -47.28 -53.87 -488.79 -496.04 -488.34 -494 -65.8 -55.2 -57.2 -45.2
EBITDA
5.13M 6.77M 1.76M 3.42M 225K 5.56M -2.56M -9.01M -9.09M -15.32M -15.11M -21.74M -27.96M -36.98M -43.15M -36.93M -32.88M -23.56M -13.37M -14.65M
EBIT
-10.04M 747K -4.48M -3.28M -7.27M -1.81M -10.59M -17.45M -17.59M -22.24M -22.41M -29.51M -36.1M -40.17M -45.73M -38.7M -34.01M -29.28M -18.74M -19.45M
Depreciation & Amortization
5.38M 6.03M 6.24M 6.7M 7.5M 7.37M 8.83M 8.94M 9.04M 9.47M 9.13M 9.9M 10.25M 10.83M 9.83M 9.03M 8.38M 8.02M 7.99M 7.41M